Ensho Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-02-09.
Ensho Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on February 9, 2026. Its industry group is Biotechnology. It names Danielle Fry (Executive Officer), Arash Rassoulpour (Director), Carlos Solorzano (Director) (SEC Form D, February 9, 2026).
Is this your company?
Sell to companies like Ensho Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-02-09 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Ensho Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Ensho Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in New Jersey, filed within 90 days of this one, largest first.
Get an email when Ensho Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Ensho Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Ensho Therapeutics, Inc. →Get the full cited report on Ensho Therapeutics, Inc.
What the filing shows about Ensho Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Ensho Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Ensho Therapeutics, Inc.'s address as 50 Tice Boulevard, Suite 340 - #1005, Woodcliff Lake, NJ 07677.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Ensho Therapeutics, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Ensho Therapeutics, Inc. See pricing
Ensho Therapeutics, Inc. is a registered filer with the SEC (CIK 2032849) and has filed since 2024-08-06. 5 filings are on record, the latest on 2026-10-15.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Ensho Therapeutics, Inc.'s Form D of 2026-02-09 names Danielle Fry, Arash Rassoulpour, Carlos Solorzano and 2 more as its officers, directors or promoters.
Its new offerings report $35.18M sold across 4 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Danielle Fry is named as Executive Officer on the Form D that Ensho Therapeutics, Inc. filed with the SEC on 9 February 2026, one of 5 people that filing names.
Arash Rassoulpour is named as Director on the Form D that Ensho Therapeutics, Inc. filed with the SEC on 9 February 2026, one of 5 people that filing names.
Carlos Solorzano is named as Director on the Form D that Ensho Therapeutics, Inc. filed with the SEC on 9 February 2026, one of 5 people that filing names.
Eric Pham is named as Director on the Form D that Ensho Therapeutics, Inc. filed with the SEC on 9 February 2026, one of 5 people that filing names.
Gerhard Hagn is named as Executive Officer on the Form D that Ensho Therapeutics, Inc. filed with the SEC on 9 February 2026, one of 5 people that filing names.
5 people named on the filing — 2 holding an executive role and 3 as directors only.
Named as of the 2026-02-09 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Ensho Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Ensho Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ensho Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Ensho Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Ensho Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Ensho Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
https://mentionfox.com/funding/ensho-therapeutics-inc-form-d-26000001